Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + lisocabtagene maraleucel
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Oral (zanubrutinib), Intravenous (lisocabtagene Maraleucel)
01
Overview
**Zanubrutinib + lisocabtagene maraleucel** is an investigational combination therapy for hematologic malignancies, specifically studied in Richter’s syndrome (transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma into aggressive lymphoma)[1][2][3][7]. Zanubrutinib is a next-generation covalent *Bruton’s tyrosine kinase (BTK) inhibitor* that blocks B-cell receptor signaling, reducing proliferation and survival of malignant B cells. Lisocabtagene maraleucel (liso-cel) is a *CD19-directed autologous chimeric antigen receptor (CAR) T cell therapy*: patients’ T cells are genetically engineered to express a CAR targeting CD19, then expanded and reinfused to attack cancerous B cells. The combination aims to exploit complementary mechanisms: zanubrutinib impairs B-cell malignancy signaling, while liso-cel provides targeted immune cytotoxicity against CD19+ tumor cells[1][2][3][6][7].
- Brand names
- Brukinsa (zanubrutinib)Breyanzi (lisocabtagene maraleucel)
- Other names
- zanubrutinib + liso-celzanubrutinib + JCAR017
02
Targets
ITK (Interleukin 2-inducible T-cell kinase)CD19 (B lymphocyte antigen CD19)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + lisocabtagene maraleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + lisocabtagene maraleucel.